Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis

Inclusion Criteria: 1. Subject has signed the informed consent form and Health Information Portability and Accountability Act (HIPAA) authorization form; 2. Male or female subject at least 18 years of age; 3. A diagnosis of stable plaque-type psoriasis vulgaris with at least one pair of symmetric lesions on either the trunk, arms, or legs that would serve as target lesions. Paired target lesions must be in similar anatomic locations (e.g., right and left elbows or right and left knees) and have roughly equivalent (no more than one point difference) modified Psoriasis Area Severity Index (PASI) scores. Each paired target lesions must have PASI scores equal to or greater than 7; 4. Any additional diagnoses must, in the investigator's opinion, not preclude the subject from safely participating in this study or interfere with the evaluation of the subject's psoriasis; 5. Psoriasis must be clinically stable for at least 30 days before enrollment; 6. Subject is able to discontinue the use of any medication or therapy for relief of psoriasis in the target areas to be treated; 7. Subject is able to discontinue the use of any systemic medication or therapy (e.g. oral or injectable psoriasis medications, PUVA photochemotherapy, herbal remedies, etc.) for psoriasis; 8. Subject must be reliable and mentally competent to complete study measurements; 9. Subject is able to understand and agrees to comply with study requirements, attend study visits, and comply with the restrictions during the study. Exclusion Criteria: 1. Subject has a skin disorder other than psoriasis in the target areas to be evaluated; 2. Known hypersensitivity to any component of the test medications; 3. Pigmentation, extensive scarring, or pigmented lesions in affected areas that would interfere with evaluation of efficacy parameters; 4. Clinically infected psoriasis at baseline; 5. Guttate, pustular, erythrodermic, or other non-plaque forms of psoriasis; 6. Spontaneously worsening or improving psoriasis within 30 days of enrollment; 7. Any evidence of atrophy in the areas selected for treatment with topical corticosteroid; 8. Topical or intralesional therapies (other than emollients) or UVB phototherapy on potential target lesions within two weeks of starting study treatment; 9. Systemic therapy, PUVA phototherapy, or a systemic investigational therapy for psoriasis within 30 days prior to study entry; 10. Treatment with topical investigational therapy of the target lesions within 30 days prior to study entry; 11. Subject is considered unreliable as to medication compliance or adherence to scheduled appointments as determined by the investigators. 12. Subject is pregnant